Literature DB >> 31018955

Incidence and outcomes of unstable angina compared with non-ST-elevation myocardial infarction.

Christian Puelacher1,2, Mathias Gugala2, Philip D Adamson3, Nicholas L Mills4, Christian Mueller2, Anoop Shah5, Andrew R Chapman6, Atul Anand3, Zaid Sabti2, Jasper Boeddinghaus2, Thomas Nestelberger2, Raphael Twerenbold2, Karin Wildi2, Patrick Badertscher2, Maria Rubini Gimenez2,7, Samyut Shrestha1,2, Lorraine Sazgary1,2, Deborah Mueller2, Lukas Schumacher2, Nikola Kozhuharov2, Dayana Flores2, Jeanne du Fay de Lavallaz2, Oscar Miro8, Francisco Javier Martín-Sánchez9, Beata Morawiec10, Gregor Fahrni11, Stefan Osswald11, Tobias Reichlin11,12.   

Abstract

OBJECTIVE: Assess the relative incidence and compare characteristics and outcome of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI).
DESIGN: Two independent prospective multicentre diagnostic studies (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] and High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome [High-STEACS]) enrolling patients with acute chest discomfort presenting to the emergency department. Central adjudication of the final diagnosis was done by two independent cardiologists using all clinical information including serial measurements of high-sensitivity cardiac troponin (hs-cTn). All-cause death and future non-fatal MI were assessed at 30 days and 1 year.
RESULTS: 8992 patients were enrolled at 11 centres. UA was adjudicated in 8.9%(95% CI 8.0 to 9.7) and 2.8% (95% CI 2.3 to 3.3) patients in APACE and High-STEACS, respectively, and NSTEMI in 15.1% (95% CI 14.0 to 16.2) and 13.4% (95% CI 12.4 to 14.3). Coronary artery disease was pre-existing in 73% and 76% of patients with UA. At 30 days, all-cause mortality in UA was substantially lower as compared with NSTEMI (0.5% vs 3.7%, p=0.002 in APACE, 0.7% vs 7.4%, p=0.004 in High-STEACS). Similarly, at 1 year in UA all-cause mortality was 3.3% (95% CI 1.2 to 5.3) vs 10.4% (95% CI 7.9 to 12.9) in APACE, and 5.1% (95% CI 0.7 to 9.5) vs 22.9% (95% CI 19.3 to 26.4) in High-STEACS, and similar to non-cardiac chest pain (NCCP). In contrast, future non-fatal MI in APACE was comparable in UA and NSTEMI (11.2%, 95% CI 7.8 to 14.6 and 7.9%, 95% CI 5.7 to 10.2), and higher than in NCCP (0.6%, 95% CI 0.2 to 1.0).
CONCLUSIONS: The relative incidence and mortality of UA is substantially lower than that of NSTEMI, while the rate of future non-fatal MI is similar. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acute coronary syndrome; mortality; myocardial infarction; unstable angina pectoris

Mesh:

Substances:

Year:  2019        PMID: 31018955     DOI: 10.1136/heartjnl-2018-314305

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

1.  Temporal Evolution of Serum Concentrations of High-Sensitivity Cardiac Troponin During 1 Year After Acute Coronary Syndrome Admission.

Authors:  Victor J van den Berg; Rohit M Oemrawsingh; Victor A W M Umans; Isabella Kardys; Folkert W Asselbergs; Pim van der Harst; Imo E Hoefer; Bas Kietselaer; Timo Lenderink; Anton J Oude Ophuis; Ron H van Schaik; Robbert J de Winter; K Martijn Akkerhuis; Eric Boersma
Journal:  J Am Heart Assoc       Date:  2020-12-16       Impact factor: 5.501

2.  Comparison of GRACE and TIMI risk scores in the prediction of in-hospital and long-term outcomes among East Asian non-ST-elevation myocardial infarction patients.

Authors:  Lu Yanqiao; Lan Shen; Miao Yutong; Shen Linghong; He Ben
Journal:  BMC Cardiovasc Disord       Date:  2022-01-07       Impact factor: 2.298

3.  Long-term predictors of death among Tunisian patients presenting for non ST-elevation acute coronary syndrome.

Authors:  Walid Jomaa; Ouday Benabdeljelil; Ikram Chamtouri; Wajih Abdallah; Khaldoun Ben Hamda; Faouzi Maatouk
Journal:  Tunis Med       Date:  2021 Juillet

4.  Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe.

Authors:  Petr Toušek; David Bauer; Marek Neuberg; Markéta Nováčková; Petr Mašek; Petr Tu Ma; Viktor Kočka; Zuzana Moťovská; Petr Widimský
Journal:  Eur Heart J Suppl       Date:  2022-03-30       Impact factor: 1.624

Review 5.  Unstable Angina as a Component of Primary Composite Endpoints in Clinical Cardiovascular Trials: Pros and Cons.

Authors:  Anna Meta Dyrvig Kristensen; Manan Pareek; Kristian Hay Kragholm; Thomas Steen Gyldenstierne Sehested; Michael Hecht Olsen; Eva Bossano Prescott
Journal:  Cardiology       Date:  2022-05-10       Impact factor: 2.342

6.  Outcomes after coronary angiography for unstable angina compared to stable angina, myocardial infarction and an asymptomatic general population.

Authors:  Kristina Fladseth; Tom Wilsgaard; Haakon Lindekleiv; Andreas Kristensen; Jan Mannsverk; Maja-Lisa Løchen; Inger Njølstad; Ellisiv B Mathiesen; Thor Trovik; Svein Rotevatn; Signe Forsdahl; Henrik Schirmer
Journal:  Int J Cardiol Heart Vasc       Date:  2022-07-31

7.  High-Sensitivity Cardiac Troponin Impact on the Differential Diagnosis of Non-ST Segment Elevation Coronary Syndromes-Is It Helping?

Authors:  Kristina Šulskutė; Aistė Pilkienė; Emilija Meškėnė; Džiugilė Kersnauskaitė; Rokas Šerpytis; Žaneta Petrulionienė; Pranas Šerpytis
Journal:  Medicina (Kaunas)       Date:  2022-08-11       Impact factor: 2.948

8.  Management and outcomes of patients with unstable angina with undetectable, normal, or intermediate hsTnT levels.

Authors:  Evangelos Giannitsis; Moritz Biener; Hauke Hund; Matthias Mueller-Hennessen; Mehrshad Vafaie; Jochen Gandowitz; Christoph Riedle; Julia Löhr; Hugo A Katus; Kiril M Stoyanov
Journal:  Clin Res Cardiol       Date:  2019-07-19       Impact factor: 5.460

9.  Outcome of acute myocardial infarction versus stable coronary artery disease patients treated with coronary bypass surgery.

Authors:  Markus Malmberg; Jarmo Gunn; Päivi Rautava; Jussi Sipilä; Ville Kytö
Journal:  Ann Med       Date:  2020-09-14       Impact factor: 4.709

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.